Skip to Content
  • Alnylam Breaks Through

    As a pioneer in RNAi therapeutics, Alnylam has really had some ups and downs over the years (some of them chronicled on this blog). Today would be one of the &# Read More
  • Turmoil in Immuno-oncology

    Immuno-oncology! It’s such a big deal, let’s just do what everyone in the field is doing and call it “IO”. The recent successes in this… Read More
  • The First Deuterated Drug Arrives

    The first deuterated drug has finally been approved by the FDA. It’s Austedo (deutetrabenazine), from Teva, and it targets Huntington’s chorea. This… Read More
  • Macrocycles For the Making

    I meant to write about this paper at the time, but there’s no harm in highlighting it now. A group at the University of Toronto reports a neat way to make… Read More
  • How Not to Do It: Dosing Volunteers

    Well, here I post about the ethical problems of using normal volunteers in Phase I studies, and this story comes along. It’s not exactly an investigationa… Read More
  • Curcumin Will Waste Your Time

    I really enjoyed reading this article in J. Med. Chem. on curcumin. (Update: here’s the take over at Practical Fragments). That’s a well-known natur… Read More
  • A New Way to Make GSK3 Inhibitors

    Of the discovery of GSK3 (glycogen synthase kinase 3) inhibitors there has been no end. I first came across it as a target it about 1997, and even then, once I… Read More
Page 1 of 812345...Last »